{"id":900662,"date":"2025-10-27T14:25:00","date_gmt":"2025-10-27T18:25:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/"},"modified":"2025-10-27T14:25:00","modified_gmt":"2025-10-27T18:25:00","slug":"edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/","title":{"rendered":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025"},"content":{"rendered":"

<\/p>\n

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025<\/b><\/p>\n

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years<\/i><\/b><\/p>\n

SAN FRANCISCO–(BUSINESS WIRE<\/a>)–
\nEdwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards\u2019 leadership in setting the standard for lasting valve performance and excellent patient outcomes across all risk profiles and generations of the SAPIEN valve.<\/p>\n

\nPresented during a late-breaking session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, and published concurrently in The New England Journal of Medicine<\/i>, the seven-year analysis marks the most extensive clinical follow-up to date for low risk transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) patients. At seven years, the data showed statistically comparable long-term valve performance between SAPIEN 3 TAVR and SAVR. Valve durability indicators remained excellent and stable over time, with no difference in bioprosthetic valve failure (6.9% vs. 7.3%) or reintervention rates (6.0% vs. 6.7%). Both all-cause and cardiovascular mortality rates were similar between cohorts. Significant improvements in health status and quality of life after treatment with SAPIEN 3 TAVR and SAVR were sustained.<\/p>\n

\n\u201cThe PARTNER trials set out to determine whether TAVR could be a safe and effective, less invasive alternative to surgery,\u201d said PARTNER 3 co-principal investigator Martin Leon, M.D., professor of medicine at New York-Presbyterian Columbia University Irving Medical Center and founder and chairman emeritus of the Cardiovascular Research Foundation. \u201cIn the PARTNER 3 low risk trial, we again see the early clinical benefit of TAVR with SAPIEN 3 over surgery, as well as excellent long term valve performance and durability results for both therapies at seven years, which should be reassuring to patients and their physicians.\u201d<\/p>\n

\nAlso at TCT, Edwards will highlight more than a decade of research from the PARTNER Trial series, including the 10-year follow up of more than 3,000 intermediate-risk patients from PARTNER 2 and PARTNER 2 S3i. These studies also demonstrate longer-term valve performance, durability and consistent clinical outcomes of Edwards TAVR.<\/p>\n

\n\u201cInsights from the PARTNER Trial series are foundational to TAVR, inspiring confidence in the procedure, advancing the therapy and fueling structural heart innovation,\u201d said Dan Lippis, corporate vice president, transcatheter aortic valve replacement. \u201cThese latest findings reinforce the undeniable early benefits of TAVR and validate its long-term durability, matching surgery in key outcomes. As the global leader in transcatheter valve therapy, we remain committed to advancing the science of aortic valve disease \u2013 including symptomatic and asymptomatic severe stenosis as well as moderate stenosis \u2013 to transform care for patients worldwide.\u201d<\/p>\n

\nSince its introduction more than two decades ago, SAPIEN has become the most studied valve platform, with more than 1 million patients treated worldwide.<\/p>\n

Dr. Leon is a consultant to Edwards Lifesciences.<\/i><\/p>\n

About Edwards Lifesciences<\/b><\/p>\n

\nEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com<\/a> and follow us on LinkedIn<\/a>, Facebook<\/a>, Instagram<\/a> and YouTube<\/a>.<\/p>\n

\nThis news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as \u201cmay,\u201d \u201cmight,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201ccontinue,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201coptimistic,\u201d \u201caspire,\u201d \u201cconfident\u201d and other forms of these words and include, but are not limited to, statements made by Mr. Lippis and statements regarding clinical outcomes and long-term clinical benefits, valve durability and performance, relative valve performance and length of life and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.<\/p>\n

\nForward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company’s filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.<\/p>\n

\nEdwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER II, PARTNER 3, RESILIA, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251027951599\/en\/<\/a><\/span><\/p>\n

\nMedia Contact: Heather Bukant, 949-250-2753
\n
Investor Contact: Mark Wilterding, 949-250-6826<\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Cardiology Medical Devices<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards\u2019 leadership in setting the standard for lasting valve performance and excellent patient outcomes across all risk profiles and generations of the SAPIEN valve. Presented during a late-breaking session at Transcatheter … <\/p>\n

Continue reading “Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900662","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEdwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards\u2019 leadership in setting the standard for lasting valve performance and excellent patient outcomes across all risk profiles and generations of the SAPIEN valve. Presented during a late-breaking session at Transcatheter … Continue reading "Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T18:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025\",\"datePublished\":\"2025-10-27T18:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/\"},\"wordCount\":910,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/\",\"name\":\"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-10-27T18:25:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/","og_locale":"en_US","og_type":"article","og_title":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - Market Newsdesk","og_description":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards\u2019 leadership in setting the standard for lasting valve performance and excellent patient outcomes across all risk profiles and generations of the SAPIEN valve. Presented during a late-breaking session at Transcatheter … Continue reading \"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-27T18:25:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025","datePublished":"2025-10-27T18:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/"},"wordCount":910,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/","name":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-10-27T18:25:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027951599r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-sapien-3-tavr-delivers-proven-long-term-benefits-and-valve-performance-new-data-presented-at-tct-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900662"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}